

PROTHELIAL™ (POLYMERIZED CROSS-LINKED HIGH POTENCY SUCRALFATE): MEDICAL DEVICE THERAPY FOR TREATMENT AND PREVENTION OF MUCOSITIS

Ricky W. McCullough MD MSc

Department of Medicine & Emergency Medicine
Veterans Administration Medical Center, Teaching Hospital
Warren Alpert Medical School of Brown University
Providence, Rhode Island 02908 USA

Department of Emergency Medicine Roger Williams Medical Center
Providence, Rhode Island 02908 USA
a Boston University School of Medicine Teaching Hospital

ABSTRACT

Effective management of mucositis in cancer patients permits oncologists to optimize treatment regimens, achieve superior outcomes and maximize survival. To date there has been limited therapeutic options available to oncologists for effective mucositis management. ProThelial™ polymerized cross-linked high potency sucralfate recently cleared by the U.S. Food and Drug Administration as a hydrogel medical device for the management (treatment and prevention) of oral mucositis. In contradistinction to other mucositis interventions, ProThelial™ has been associated with 2-3 day rapid reversal of oral mucositis, complete prevention of oral mucositis and reversal of small bowel and colonic mucositis. It is likely to substantially impact the management of oral mucositis in patients undergoing treatment for cancer.

Keywords: Sucralfate, Mucositis, ProThelial, Chemo-radiation induced, Polymerized Sucralfate.